key: cord-0960034-n3oztulg
authors: Ali, Nemat; Prasad, Kartikay; AlAsmari, Abdullah F.; Alharbi, Metab; Rashid, Summya; Kumar, Vijay
title: Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation
date: 2021-11-01
journal: Int J Biol Macromol
DOI: 10.1016/j.ijbiomac.2021.09.018
sha: 07fa13cb54a495c6be867e7bf50136d3e6a11886
doc_id: 960034
cord_uid: n3oztulg

SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-induced phase separation (LLPS) and sequesters the host key stress granule (SG) proteins, Ras-GTPase-activating protein SH3-domain-binding protein 1 and 2 (G3BP1 and G3BP2) to inhibit SG formation. This will allow viral packaging and propagation in host cells. Based on a genomic-guided meta-analysis, here we identify upstream regulatory elements modulating the expression of G3BP1 and G3BP2 (collectively called G3BP1/2). Using this strategy, we have identified FOXA1, YY1, SYK, E2F-1, and TGFBR2 as activators and SIN3A, SRF, and AKT-1 as repressors of G3BP1/2 genes. Panels of the activators and repressors were then used to identify drugs that change their gene expression signatures. Two drugs, imatinib, and decitabine have been identified as putative modulators of G3BP1/2 genes and their regulators, suggesting their role as COVID-19 mitigation agents. Molecular docking analysis suggests that both drugs bind to G3BP1/2 with a much higher affinity than the SARS-CoV-2 N protein. This study reports imatinib and decitabine as candidate drugs against N protein and G3BP1/2 protein.

The recent outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the greatest public health challenges in recent times, leading to unprecedented growth in research efforts to develop vaccines and therapeutics [1] . The novel SARS-CoV-2 is an enveloped, singlestranded, positive-sense ~30 kb RNA virus of the family Coronaviridae [1] . The SARS-CoV-2 membrane contains the spike (S) glycoprotein, a membrane (M) protein, the envelope (E) protein, and nucleocapsid (N) protein. The N protein encapsulates the viral genome and thereby protects it from the host cell environment [2] . In the infected cells, the N protein is produced at high levels and is necessary for virion assembly and replication [3, 4] . Moreover, it enhances the transcription efficiency of sub-genomic viral RNA, thus modulates host cell metabolism [2] . SARS-CoV-2 N protein is a 46 kDa RNA-binding protein, containing an Nterminal RNA-binding domain, and a C-terminal oligomerization domain. These two domains are connected by a linker region comprising a serine/arginine-rich (SR rich) domain (SRD) [5] [6] [7] .

nucleators of SG formation [14, 20] , and overexpression of these proteins leads to SG formation even in the absence of stress [21] .

Very recently, Syed Nabeel-Shah et al. [13] have shown that the SARS-CoV-2 N protein interacts and sequesters G3BP1 and decreases SG formation. In contrast, ectopic expression of G3BP1 attenuates this inhibition in N-expressing cells. Therefore, the upregulation of G3BP1/2 may have a protective effect on SARS-CoV-2 infections by decreasing the viral load.

To get more insights into the regulation of G3BP1/2 expression, we have performed gene set enrichment analysis (GSEA) to find out the upstream regulatory elements modulating the expression of G3BP1/2 genes. Drugs were then identified based on their ability to change the gene expression of the identified regulators of G3BP1/2 genes. Using this strategy, we have identified and evaluated imatinib and decitabine as the two drugs that could be repurposed to ameliorate the outcomes of COVID-19. Further, similar to our previous studies [22] [23] [24] , we have utilized the network-based methods to examine the drug-gene interactions between drugs and human targets of SARS-CoV-2 proteins identified through three different proteomics-based studies [11] [12] [13] .

The advantage of GSEA is that it provides a framework to investigate the gene expression alterations related to a disease that can be evident at the level of biological pathways or coregulated gene sets, rather than individual genes. Thus, we checked here the expression changes of individual genes reported in different GEO studies.

In this study, GSEA was carried out to identify the genes linked to G3BP1 and G3BP2 for the genes from more than 100 gene set libraries [25, 26] . To this end, GSEA was performed using G3BP1/2 genes as baits applied to the genomic databases about the functional, regulatory, and pathophysiological features associated with these genes. Enrichment analysis infers knowledge about gene (s) by comparing it to gene sets that have already been annotated and searching for overlap.

The transcription factors regulating the expression of G3BP1/2 and the kinases co-expressed with G3BP1/2 were identified and considered as regulators of G3BP1/2 genes. Drugs were then identified based on their effects on gene expression signatures of the regulators of G3BP1/2 genes. The screening for enrichment was based on the "combined score" which is a product of the log of the p-value obtained from the Fisher's exact test and the z-score, which is a deviation from the expected rank (i.e., combined score, c = log(p)*z). Next, the validation of the GSEA results was done by using the GEO2R tool of the NCBI and manual curations of the gene expression profiles of the Gene Expression Omnibus (GEO) database. GEO2R tool compares two or more groups of samples to identify the genes that are differentially expressed across experimental conditions. The tool in the background uses the limma package of R language to perform widely used statistical tests to identify the differentially expressed genes.

the drug-protein interaction network of the predicted drugs with these 809 human proteins was constructed and studied using Cytoscape [27] .

Using a network-based approach, we have identified imatinib and decitabine as target molecules for G3BP1 and G3BP2 genes. The three-dimensional structures of G3BP1 (PDB Id: 4FCJ) and G3BP2 (PDB Id: 5DRV) along with the N-terminal domain of SARS-CoV-2 N protein (NTD, PDB Id: 6M3M) were retrieved from the protein data bank database [28] . The three-dimensional structures were energy minimized using the Swiss PDB Viewer (SPDBV) tool [29] . For protein-protein docking, the HDOCK tool was used [30] . HDOCK is based on a hybrid algorithm of template-based modeling and ab initio free docking. The mol file of imatinib and decitabine was retrieved from the DrugBank database [31] . The OpenBabel software [32] was used for converting the mol file into a PDB file having 3D structural coordinates of the drug molecules. For protein-ligand docking, AutoDock-Vina [33] was utilized. The site-specific docking was performed with a grid spacing of 1Å, and exhaustiveness of 8. From the binding affinity of protein-ligand complexes, the best docking pose was generated and analysed using PyMOL (https://pymol.org/2/) and Discovery studio [34] . represented by the polar (∆G GB ) and non-polar (∆G Surf ) energy terms.

All-atom MD simulations were performed using Gromacs v5.18.3 on the atomic coordinates of G3BP1 and G3BP1-drug complexes. The CHARMM27 force field was utilized and the TIP3P was used as a water model to solvate the systems [35] . The PRODRG server [36] was utilized to generate molecular topologies and coordinate files of drug-like molecules. The G3BP1 systems were placed in the octahedral simulation box with the water molecules filling around the system. The 0.15 M counter ions (Na + and Cl -) were added to neutralize the system [37] . The energy minimization of the neutralized systems was achieved using the steepest descent and conjugate gradients (50000 steps for each). NVT (constant volume) and

NPT (constant pressure) for 500 ps were then used for the equilibration of the system.

Berendsen weak coupling method [38] and Parrinello-Rahman barostat [39] methods were employed to maintain the temperature and pressure of G3BP1 systems at 300 K, and 1 bar, respectively. LINC algorithm was used to constrain the bonds and angles [40] . The van der

The principal component analysis (PCA) is performed to extract the information on the motion of the molecules during MD simulation which is associated with biological function.

The first top two principal components (PC1and PC2) of PCA were investigated using the essential dynamics (ED) method by g_covar, g_anaeig modules. Next, PC1 and PC2 were selected as reaction coordinates for the calculation of free energy, Gα using:

Where k is the Boltzmann constant, T is the simulation temperature. P(qα) represents the probability density function of reaction coordinates (PC1 and PC2). Pmax(q) represents the probability distribution of the most probable state.

We have used the Enrichr bioinformatics platform [26] to identify human genes involved in regulatory cross-talks and modulating the expression level of G3BP1 and G3BP2 genes, thus potentially affecting SG formation and SARS-CoV-2 infection.

Expression profiling of G3BP1/2 genes revealed ubiquitous patterns of expression across human tissues. G3BP1 is highly expressed in the lung as well as gastrointestinal and respiratory tract tissues. In contrast, G3BP2 is highly expressed in different regions of the brain (Supplementary Figure S1 ). G3BP1 showed very low expression in brain and whole blood tissues whereas G3BP2 showed very low expression in whole blood, heart, and liver.

GSEA of the COVID-19 related gene sets revealed that both G3BP1 and G3BP2 belong to SARS-CoV-2 N protein host PPI from the Gordon study [42] . The different GEO records revealed that G3BP2 is a member of SARS-CoV-2 downregulated genes in Vero E6 cells Figure S4) . The GSEA analysis reported the differential regulation of these TFs in the SARS-CoV-2 gene sets available in the Enrichr platform (Supplementary Table S1 ). Table S2) .

We have also identified the TFBs in G3BP1/2 using the position weight matrices (PWMs) analysis from TRANSFAC and JASPAR. The common human binding motif site identified in the G3BP1/2 is the transcription factor, Yin Yang 1 (YY1) (Supplementary Figure S5 ). Table S1 ). Interestingly, the expression of YY1 showed a mixed response in human PBMC samples infected with SARS-CoV (GSE1739) ( Supplementary Table S2 ).

Next, we looked at the GEO database to find out the effects of these TFs on the expression Table S2 ). SIN3A knockdown showed mixed response towards the expression of G3BP1, while SIN3A knockdown increased the expression of G3BP2 (Supplementary Table S2 Table   S2 ). Both THRA and THRB decreased G3BP1 protein expression and assembly in stress granules after arsenite stimulation [44] . (Supplemental Table S1 ). Also, the GEO gene perturbations database focused on downregulated genes identified ATM (Ataxia-Telangiectasia-Mutated) and E2F-1 (E2F transcription factor 1) as putative activators and repressor of G3BP1/2, respectively (Supplementary Figure S7) . This is further validated by investigating the different GEO records of G3BP1/2 genes. ATM knockdown decreased G3BP1 and G3BP2 expression in Table S2 ). The summary of these observations is reported in Figure 2B .

A recent study presents SARS-CoV-2 infection-induced global phosphorylation changes which lead to disruption of kinases and associated pathways [45] . Table S2 ). Table 1 summarizes the overall effects of imatinib and decitabine on the G3BP1/2 gene and their putative modifiers.

Many different SARS-CoV-2-host interactome studies have identified human proteins that could be considered as important drug targets to inhibit SARS-CoV-2 infection. The three excellent SARS-CoV-2-human interactome studies identified almost 809 high-confidence human proteins interacting with the 27 SARS-CoV-2 proteins [11] [12] [13] . Assuming that the drugs which significantly alter these protein-protein interactions will also inhibit the growth of the virus, we here investigated the drug-protein interactions. We found that out of the total 

Micro-RNAs (miRNAs) are small non-coding RNAs that can bind to 3'UTR of mRNA and inhibit translation or induce mRNAs degradation [46] . Many studies showed that host cellular miRNAs can target both the coding region and 3'UTR of the viral genome to induce an antiviral effect [47, 48] . To identify potential miRNAs that can directly regulate G3BP1 and G3BP2, TargetScan microRNA 2017 and miRTarBase 2017 from the Enrichr platform have been explored. The analysis revealed two common miRNAs, hsa-miR-3925-5p, and hsa-miR-486-5p against the G3BP1/2 genes (Supplementary Figure 11) . A recent study reported the presence of hsa-miR-3925-5p in different COVID-19 isolates [49] . Another study identified hsa-miR-486-5p as a potential antiviral against the influenza A virus [50] .

Molecular docking studies are largely utilized to explore the binding modes of receptor and ligand molecules and are generally used in drug discovery. Through the molecular docking studies, we here determined the binding of imatinib and decitabine to G3BP1 and G3BP2

genes. The proposed modes of drug binding are presented in Figures 5 and 6 , and the docking results based on the binding affinity are represented in Table 2 .

As G3BP1 and G3BP2 interact directly with the SARS-CoV-2 N protein, we have utilized the HDock web server for protein-protein docking. Docking studies of G3BP1 and G3BP2

with N-protein results in the docking score of -182.53 and -202.03 respectively, indicating the stringent binding affinity with the N-protein (Supporting Figure S12) . Furthermore, the binding study of decitabine and imatinib with G3BP1/2 and N-protein was also performed.

To predict the binding pocket in the protein, a ligand-independent binding site identification was done using CASTp Server [51] . Figure 6D) . The above results suggested that imatinib binds strongly with G3BP1 and G3BP2 protein compared to decitabine.

To investigate the conformational stability of the G3BP1-drug complexes, we next performed MD simulation for 100 ns and computed root mean square deviation (RMSD) of the Cα atoms, the radius of gyration (R g ), root mean square fluctuations (RMSF), and solvent accessible surface area (SASA) of the protein. The Cα-RMSD provides a global picture of the conformational deviation in structure with respect to the initial structure during the simulation. As can be seen from Figure 7A , the drug binding induces an increase in conformational stability in the protein with the decrease in Cα-RMSD. The other structural parameters, R g and SASA were calculated to assess the structural integrity and compactness of G3BP1-drug complexes (Figure 7B and 7C) . The time evolution of R g showed that the imatinib bound G3BP1 complex has increased R g and SASA values, suggesting the potential unfolding effect of imatinib on G3BP1. However, the decitabine bound G3BP1 complex becomes more compact with lesser R g and SASA. Furthermore, RMSF showed the fluctuations of each residue in the unbound and bound G3BP1 (Figure 7D) . 

The PCA was studied to determine the important motions of the protein bound to the ligand.

The two-dimensional projection of PCA (PC1 and PC2) showed that the G3BP1-drug complexes cover a larger and different conformational subspace with high flexibility as compared to unbound G3BP1 ( Figure 8A) . The unbound G3BP1 exhibited lesser stable clusters as compared to G3BP1-drug complexes, particularly to G3BP1-decitabine. G3BP1decitabine complex showed a more stable cluster with the increased amount of the accessible subspace along PC2. Similarly, the G3BP1-imatinib complex occupied a more stable cluster and wider phase space along PC1. Thus, the G3BP1-imatinib complex has increased fluctuations and might affect the protein motions upon drug binding. These findings were further confirmed through investigating the residue displacements along with PC1 and PC2

for the G3BP1-drug complexes (Figure 8B and 8C) . The average fluctuation for the G3BP1decitabine complex was smaller as compared to the G3BP1-imatinib complex.

To examine the effects of the drug on the conformational stability of G3BP1, FEL was evaluated as a function of the top two principal components, PC1, and PC2. FEL has been utilized to successfully investigate the conformational redistributions induced by ligand binding [52] [53] [54] [55] . Figure 9 showed the relative conformational changes of G3BP1 systems where the lower energy conformational states are indicated by the deeper blue color. The FEL plots revealed ΔG values 0 to 15.9, 15.7, and 13.7 kJ/mol (Figure 9 ) for unbound G3BP1, G3BP1-decitabine, and G3BP1-imatinib complex, respectively. The FEL of unbound G3BP1 is populated by two different conformational subspaces linked by a low energy J o u r n a l P r e -p r o o f barrier ( Figure 9A ). G3BP1-decitabine complex showed a significant population shift towards a large, single, and wider energy basin consisting of a single metastable state ( Figure   9B ). The G3BP1-imatinib complex is characterized by the presence of different energy basins and a reverse population shift relative to the unbound G3BP1 system (Figure 9C) .

Further, the atomic density distribution analysed using densmap indicated that decitabine and imatinib binding increased the partial density area of G3BP1 from 1.97 nm −3 to 3.21 nm −3 and 2.27 nm −3 , respectively (Supplementary Figure S13) . The density maps thus revealed that binding of the drug especially imatinib induced a large conformation change to G3BP1.

Overall, the MD results revealed that decitabine weakly modulates G3BP1 conformations whereas, imatinib binding significantly changes G3BP1 conformations and thus could significantly regulate the protein's function.

G3BP1 and G3BP2 bind strongly with the N protein of SARS-CoV-2 and SARS-CoV than other human coronaviruses, and the binding to MERS-CoV N protein was the weakest [13] .

Recently, SARS-CoV-2 N protein has been shown to undergo phase separation that enhances viral RNA replication and translation and mediates the packaging of viral genome in host cells. The N protein sequester the SG essential protein G3BP1/2 and attenuates SG formation Imatinib is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and has been reported to inhibit SARS-CoV infection and MERS-CoV [56] [57] [58] . Mechanistic studies suggested that imatinib will be considered as a good therapeutic possibility in the COVID-19

for its demonstrated anti-inflammatory activity, SARS-CoV-2 entry inhibitor, and kinase inhibitory activity. Imatinib has also been shown to induce eIF2α phosphorylation and thus induces SG formation and promotes apoptosis [59] . Moreover, a recent study showed that the kinase inhibitor, nilotinib affects N protein phase separation with viral RNA and disrupts condensates formed by the N protein in mammalian cells [60] . Previous studies have also shown that nilotinib inhibited the proliferation of both SARS-CoV and SARS-CoV-2 [61] [62] [63] . Another study indicated imatinib as an important SARS-CoV-2 protease inhibitor using the Reframe library screen of clinical and near-clinical compounds [64] . Our results thus J o u r n a l P r e -p r o o f provide a rationale for evaluating imatinib as an antiviral agent against COVID-19.

Interestingly, three potential randomized clinical trials are underway to study the therapeutic efficacy of imatinib against COVID-19, including NCT04357613 (France), NCT04394416

(USA), and EudraCT2020-001236-10 (The Netherlands). In another study, Imatinib will be compared to hydroxychloroquine, Lopinavir/ ritonavir, and Baricitinib (NCT04346147).

Decitabine falls under the nucleotide and nucleoside analogs which are broad-spectrum antiviral drugs that inhibit transcription and/or replication of different RNA and DNA viruses by inhibition of DNA methylation [65] . A recent study showed decitabine as the potent inhibitor of RNA-dependent RNA polymerase and thus could be regarded as a drug that would inhibit viral replication and growth [66] . Recently, a randomized double-blind placebo-controlled Phase 2 trial has been initiated to assess the efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS (Clinical Trial ID: NCT04482621,   IRB00247544 ).

In conclusion, our results suggest that by targeting G3BP1/2 and their regulators, the drugs imatinib and decitabine affect the SG formation in host cells and thus could represent a viable approach in future studies of COVID-19.

V.K. designed the study, N.A., K.P., and M.A. performed the study and prepared figures of the results. A.F.A, S.R., and V.K. analysed the data and wrote the manuscript. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The coronavirus nucleocapsid is a multifunctional protein

Coronaviruses: an overview of their replication and pathogenesis

Return of the Coronavirus: 2019-nCoV

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein

Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates

SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs

The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV

SARS-CoV-2 Nucleocapsid protein attenuates stress granule formation and alters gene expression via direct interaction with host mRNAs

G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Granules

RNA-Induced Conformational Switching and Clustering of G3BP Drive Stress Granule Assembly by Condensation

Junin virus infection impairs stress-granule formation in Vero cells treated with arsenite via inhibition of eIF2alpha phosphorylation

Interaction of TIA-1/TIAR with West Nile and dengue virus products in infected cells interferes with stress granule formation and processing body assembly

Rabies Virus Infection Induces the Formation of Stress Granules Closely Connected to the Viral Factories

Novel Staufen1 ribonucleoproteins prevent formation of stress granules but favour encapsidation of HIV-1 genomic RNA

Phosphorylation of G3BP1-S149 does not influence stress granule assembly

The RasGAP-associated endoribonuclease G3BP assembles stress granules

Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective

Neurological manifestations of COVID-19: Available evidences and a new paradigm to understand the complications

Brain Disease Network Analysis to Elucidate the Neurological Manifestations of COVID-19

Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Cytoscape: a software environment for integrated models of biomolecular interaction networks

The protein data bank

SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling

The HDOCK server for integrated protein-protein docking

DrugBank: a comprehensive resource for in silico drug discovery and exploration

Open Babel: An open chemical toolbox

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Biovia, discovery studio modeling environment

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations

The missing term in effective pair potentials

Crystal Structure and Pair Potentials: A Molecular-Dynamics Study

LINCS: A linear constraint solver for molecular simulations

MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics Trajectories

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome

A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex

The Role of microRNAs in the Pathogenesis of Herpesvirus Infection

Increasing expression of microRNA 181 inhibits porcine reproductive and respiratory syndrome virus replication and has implications for controlling virus infection

Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile

Endogenous Cellular MicroRNAs Mediate Antiviral Defense against Influenza A Virus

CASTp 3.0: computed atlas of surface topography of proteins

Comparative analysis of thermal unfolding simulations of RNA recognition motifs (RRMs) of TAR DNA-binding protein 43 (TDP-43)

Delineating the effect of mutations on the conformational dynamics of N-terminal domain of TDP-43

TFE-induced local unfolding and fibrillation of SOD1: bridging the experiment and simulation studies

Alterations in local stability and dynamics of A4V SOD1 in the presence of trifluoroethanol

The CoV-2 outbreak: how hematologists could help to fight Covid-19

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

SARS CoV-2 nucleocapsid protein forms condensates with viral genomic RNA, bioRxiv

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

Repurposing of clinically developed drugs J o u r n a l P r e -p r o o f for treatment of Middle East respiratory syndrome coronavirus infection

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication, bioRxiv

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis

Novel activities of safe-in-human broad-spectrum antiviral agents

Virtual Screening and Molecular Dynamics on Blockage of Key Drug Targets as Treatment for COVID-19 Caused by SARS-CoV-2

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through research group no. RG-1441-451.

No potential conflict of interest was reported by the authors.